INCB 057643
Alternative Names: BEIi; INCB 57643; INCB057643; LIMBER-103Latest Information Update: 06 May 2024
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Oxazines; Pyridines; Pyrroles; Small molecules; Sulfones
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myelofibrosis
- No development reported Myelodysplastic syndromes
- Discontinued Cancer
Most Recent Events
- 30 Apr 2024 Incyte Corporation plans a phase III trial in the second half of 2024
- 28 Mar 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Late-stage disease, Second-line therapy or greater) in Finland (PO)